3ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[].New England Journal of Medicine The.2008
4Chobanian AV,Bakris GL,Black HR,et al.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[].Journal of the American Medical Association The.2003
5UK Prospective Diabetes Study Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes[].The Lancet.1998
6Zheng JL,Lu L,Hu J.Increased serum YKL-40 and C-reactiveprotein levels are associated with angiographic lesion progressionin patients with coronary artery disease[].Atherosclerosis.2010
7Rathcke CN,Vestergaard H.YKL-40-an emerging biomarker in cardiovascular disease and diabetes[].Cardiovascular Diabetology.2009
8Kubota N,Yano W,Kubota T,Yamauchi T,Itoh S,Kumagai H,Kozono H,Takamoto I,Okamoto S,Shiuchi T,Suzuki R,Satoh H,Tsuchida A,Moroi M,Sugi K,Noda T,Ebinuma H,Ueta Y,Kondo T,Araki E,Ezaki O,Nagai R,Tobe K,Terau-chi Y,Ueki K,Minokoshi Y,Kadowaki T.Adiponectin stim-ulates AMP-activated protein kinase in the hypothalamus and increases food intake[].Cell Metab.2007
9Vijan S,Hayward RA.Pharmacologic lip-id-lowering therapy in type2diabetes mellitus:backgroud paper for the A-merican College of Physicians[].Annals of Internal Medicine.2004
10Cao Y,Tao L,Yuan Y,et al.Endo-thelial dysfunction in adiponectin de-ficiency and its mechanisms involved[].Journal of Molecular and Cellular Cardiology.2009
4Aycher SL,Huang JMC,Hampl V,et al.Nitric oxide and cGMP cause vasorelaxation by activation of a charybolotoxin-sen-sitve K channel by cGMP-dependent protein kinase[J].Pron Natl Sci USA,1994,91:7583.
5Srikanth S,Deedwania P.Management of coronary artery disease in patients with type 2 diabetes mellitus.Curr Cardiol Rep,2007,9:264-271.
6Flaherty JD,Davidson CJ.Diabetes and coronary revascularization.JAMA,2005,293:1501-1508.
7Stenestrand U,James SK,Lindback J,et al.Safety and efficacy of drug-eluting vs.bare metal stents in patients with diabetes mellitus:long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).Eur Heart J,2010,31:177-186.
8Stettler C,Allemann S,Wandel S,et al.Drug eluting and bare metal stents in people with and without diabetes:collaborative network meta-analysis.BMJ,2008,337:a1331.
9Simonton CA,Brodie B,Cheek B,et al.Comparative clinical outcomes of paclitaxel-and sirolimus-eluting stents:results from a large prospective multicenter registry--STENT Group.J Am Coll Cardiol,2007,50:1214-1222.
10Iakovou I,Schmidt T,Bonizzoni E,et al.Incidence,predictors,and outcome of thrombosis after successful implantation of drug-eluting stents.JAMA,2005,293:2126-2130.
